LENZ Therapeutics, Inc. LENZ R2KR3KPHARMA
Company Overview
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -84.86% |
| 6 Months: | -48.93% |
| 3 Months: | -14.98% |
| 1 Month: | +14.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)67.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LENZ LENZ Therapeutics, Inc. R2KR3KPHARMA | 5.96 | -1.64 | $186.87M | 0.00% | -32.01% | -49.71% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 1.90M |
| Operating Income | -1.29M | -3.76M | -9.37M | -17.53M | -14.60M | -25.96M | -26.78M | -26.15M | -12.62M | -14.96M | -19.86M | -16.09M | -14.35M | -12.95M | -16.93M | -16.86M | -18.89M | -44.13M |
| Net Income | -1.31M | -3.38M | -19.71M | -17.53M | -14.59M | -25.84M | -25.94M | -24.68M | -12.67M | -14.73M | -18.88M | -16.65M | -10.25M | -10.21M | -14.62M | -14.91M | -16.70M | -41.49M |
| Diluted EPS | - | - | - | -3.45 | -0.28 | -0.48 | -0.48 | -0.45 | -6.50 | -7.53 | -9.62 | -3.53 | -0.40 | -0.38 | -0.53 | -0.53 | -0.59 | -1.32 |
| R&D Expense | 423.00K | 2.31M | 5.38M | 12.67M | 8.68M | 18.25M | 17.78M | 18.30M | 10.32M | 12.64M | 17.00M | 10.54M | 6.95M | 6.45M | 5.82M | 9.06M | 3.79M | 0 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 19.09M |
| Operating Income | -13.50M | -60.44M | -105.64M | -72.43M | -58.61M | -91.14M |
| Net Income | -68.37M | -70.76M | -101.05M | -69.97M | -49.77M | -82.13M |
| Diluted EPS | - | -2.45 | -1.84 | -35.71 | -2.34 | -2.85 |
| R&D Expense | 9.12M | 37.93M | 72.79M | 59.50M | 29.80M | 18.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.56M | 401.99M | 321.90M | 70.38M | 215.30M | 305.88M |
| Total Equity | -2.22M | -65.41M | 384.05M | -24.17M | -92.71M | 204.08M | 284.34M |
| Cash & Equivalents | - | 19.78M | 376.98M | 47.73M | 35.14M | 20.16M | 25.18M |
| Total Liabilities | - | 32.36M | 17.94M | 25.61M | 19.70M | 11.22M | 21.54M |
| Current Liabilities | - | 32.05M | 12.14M | 13.04M | 18.51M | 10.41M | 21.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.72M | -52.85M | -87.98M | -60.38M | -59.39M | -69.17M |
| Investing Cash Flow | -1.54M | -5.74M | -241.86M | -29.62M | -154.48M | -75.67M |
| Financing Cash Flow | 30.08M | 417.47M | 597.00K | 80.70M | 199.00M | 149.75M |
| Capital Expenditure | -1.54M | -5.74M | -6.59M | -30.00K | -468.00K | -827.00K |
| Free Cash Flow | -10.27M | -58.59M | -94.57M | -60.41M | -59.86M | -70.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -477.5% |
| Net Margin % | - | - | - | - | - | -430.3% |
| ROE % | 104.5% | -18.4% | 418.1% | 75.5% | -24.4% | -28.9% |
| ROCE % | 142.3% | -15.5% | -34.2% | -139.7% | -28.6% | -32.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 13.30% | 4.18M | $21.35M |
| 2 | Alpha Wave Global, LP | 11.50% | 3.61M | $18.46M |
| 3 | FMR, LLC | 11.33% | 3.56M | $18.19M |
| 4 | Versant Venture Management, LLC | 8.46% | 2.66M | $13.58M |
| 5 | Blackrock Inc. | 7.30% | 2.29M | $11.71M |
| 6 | Squarepoint Ops LLC | 5.56% | 1.75M | $8.93M |
| 7 | Aberdeen Group plc | 4.93% | 1.55M | $7.91M |
| 8 | Millennium Management Llc | 4.80% | 1.51M | $7.71M |
| 9 | Vanguard Capital Management LLC | 3.49% | 1.10M | $5.61M |
| 10 | 72 Investment Holdings, LLC | 3.24% | 1.02M | $5.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LENZ
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPakNNYS1VeHpBWEV2ZXZ3NmpDRzRBb3VoTFNWME5yQmhyNm5tbGVLRkhfMHRZV3d2MDdvOVF1eWw1eHRXX1pSZXhrSThCNkY5SzZfa1JvUE1hYjcyazRFNkhia0kzOFVERDBxQmRMTVlzQjNrNlRSb19PVFFVMGFTUXd3WjFUSWp1c19ybl…
LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQUVFQcjk5SmRqdWJic1NydGxCU1RBQ1RzaHowQzZQWVE0OFRtQi1neVVGbXBJbU1TUmpsQmRGTEVsZExfX1pRY0lFUXp4cmI0WkhZa042SGhzdzhwdnlQOHctYUpld0wtUDZ0VVZ3c2pqeVZ0VHpjT2ZRdXdndmpQY2llcVJkcFI5cnB2NW…
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - LENZ Therapeutics
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOZHJ0NFY5Ymc3Z2VGd2tSRGVIMGpnSG0yOTVkamVwZm1KU0RSSkx5RUtsUnh4M1RoMUtjeFlKQU5IZG9zMUwwS3Y1NUhpaE81Z1JRSGEwWkQyUUN6RUtzcWwzbnlpaWl5WnFLWGhQUmFJc3p1MUNqN3JGSFIzbGlHS3BReWN5S2VmV1pYXz…
LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOd1JyaGJ0NERGR0h5YmdzaVNMRHdnbXlKVlllOTc2azBmUDU3SE1CRFprWDVTT2lXNTFVcVBHbFU1Nktfc01EYzVlNEFoai1JUHNxSkFSZTN5dUJDLXU4SGlYOWNBeENsVjdoVzFYelB2QV9WZ2V3UW40VEVhekVGVGo1UnhmaFgwZXVXa2…
LENZ THERAPEUTICS ($LENZ) Releases Q2 2026 Earnings, Stock Rises - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeHVQQ2lwME9WT1FKclVnYU5iN3dqaUtqUi1tb0w3djZCanVSQWl1RUlzRHJnVVRuZTlISFctTnZ6Ym1HWTZpYVBXX1JSYVdzTU1nRlZZb25IN3lwVWl0TTBrMXpCMjZTZVN3Y3RTeldSQUZ1d2xPdGdEM3ctbWgxQlpmcFVISG5QZ1BZWF…
Lenz Therapeutics faces securities fraud probe after weak product sales and stock plunge. - Pluang
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQZEdfR0w2SmJQSHlYSnAwUmpoZ1JLWGx5Nmdpc3Iydnl1Y0lURmdsdDdzZzI4Q0VlR0ZFbWFDeGRGVmVnVFhld2tjeUY4cnV6c0NhNGk0S3dLbEVFd0FlaDlwXzg0TlItN21rbUpVdXNvQ0VhRmM4czFLeW1sb0Z3YWxpRUxpNXVlVkxnVU…
LENZ — Frequently Asked Questions
What is the current share price of LENZ Therapeutics, Inc. (LENZ)?
As of 2026-09-07 16:24 PDT, LENZ Therapeutics, Inc. (LENZ) trades at $5.96 on NasdaqGS. Its 52-week range is $4.59 to $49.05.
What is the market capitalisation of LENZ?
LENZ Therapeutics, Inc. (LENZ) has a market capitalisation of $186.87M on NasdaqGS.
What is the P/E ratio of LENZ?
LENZ trades at a trailing price-to-earnings (P/E) ratio of -1.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.68.
What is the return on equity (ROE) of LENZ?
LENZ has a return on equity (ROE) of -49.71%. Its return on capital employed (ROCE) is -32.01%.
Is LENZ a good stock to buy?
This page provides a data-driven analysis of LENZ Therapeutics, Inc. (LENZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.